ImmunoGen Announces Webcast of Presentation and Q&A at the 35th Annual J. P. Morgan Healthcare Conference
December 28 2016 - 8:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
announced that Mark Enyedy, President and CEO, will present at the
upcoming 35th Annual J. P. Morgan Healthcare Conference in San
Francisco. The presentation is scheduled for 2:30 pm PT (5:30 pm
ET) on January 11, 2017.
Following the presentation, Mr. Enyedy will be joined by other
members of ImmunoGen’s management team for a question-and-answer
session at 3:00 pm PT (6:00 pm ET).
A webcast of the presentation and question-and-answer session
will be accessible live through the "Investors" section of the
Company's website, www.immunogen.com; a replay will be
available at the same location for approximately a week.
About ImmunoGenImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. ImmunoGen’s lead product
candidate, mirvetuximab soravtansine, is in a Phase 3 trial for
FRα-positive platinum-resistant ovarian cancer, and is in
Phase 1b/2 testing in combination regimens for earlier-stage
disease. ImmunoGen’s ADC technology is used in Roche's marketed
product, Kadcyla®, in three other clinical-stage ImmunoGen product
candidates, and in programs in development by partners Amgen,
Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161228005025/en/
ImmunoGen, Inc.Investor Contact:Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMedia Contacts:Amy
Reilly, 781-895-0138amy.reilly@immunogen.comorFTI Consulting,
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024